The sensitive detection of low molecular mass peptide drugs in dried blood spots by solid-phase extraction and LC-HRMS

• Published in: Analytical and bioanalytical chemistry 2024-11, Vol.416 (26), p.5655-5669
• Main Authors: Chang, Wei, Yan, Siyu, Yan, Xiya, Wang, Zhanliang, Gu, Boya, Liu, Yunxi, Zhang, Yufeng, Yang, Sheng
• Format: Article
• Language: English
• Subjects: Analytical Chemistry; Biochemistry; Blood; Characterization and Evaluation of Materials; Chemistry; Chemistry and Materials Science; Chromatography, Liquid - methods; Doping; Doping in Sports - prevention & control; Dried Blood Spot Testing - methods; Drug development; Drugs; Food Science; Humans; Ionization; Laboratory Medicine; Limit of Detection; Mass spectrometry; Mass Spectrometry - methods; Mass spectroscopy; Molecular Weight; Monitoring/Environmental Analysis; Peptides; Peptides - blood; Peptides - urine; Research Paper; Solid Phase Extraction - methods; Solid phases; Substance Abuse Detection - methods
• ISSN: 1618-2642; 1618-2650; 1618-2650
• DOI: 10.1007/s00216-024-05480-w

Dried blood spot (DBS) technique has become a new popular topic in anti-doping field in recent years due to its advantages of sample stability and easy operation. It can be employed as a supplementary method to routine urine analysis. However, the small volume of DBS samples (usually 10–20 μL) significantly reduces the application value of this technique. Therefore, the development of sensitive detection methods for the analysis of prohibited substances in DBS is particularly important. In this study, based on the characteristics of low molecular mass peptide (LMMP) drugs, systematic optimization strategies were utilized for the first time to establish a sensitive detection method for LMMPs in DBS. Without using DMSO to enhance mass spectrometry ionization efficiency of peptides, the limits of detection (LOD) ranged between 0.05 and 3.74 ng/mL, significantly better than the previously reported method (0.5–20 ng/mL). This method was validated according to the guidelines of the World Anti-Doping Agency (WADA), and corresponding post-administration study was conducted, demonstrating that the method could be applied to routine analysis of LMMP drugs in DBS. Moreover, since DMSO is not involved, this method also has the potential to simultaneously detect both LMMP and small molecular drugs. Graphical Abstract